November 13, 10:00 a.m. GMT – Dr. Given will deliver a poster presentation titled, “Targeting HIF2α with an RNAi therapeutic for the treatment of clear cell renal cell carcinoma”

November 12, 10:45 a.m. CST – Rui Zhu, Ph.D., Arrowhead’s senior chemist, will deliver an oral presentation titled, “RNA Interference Mediated Apolipoprotein C3 Gene Silencing as a Therapeutic for Hypertriglyceridemia”

November 12, 11:45 a.m. CST – So Wong, Ph.D., Arrowhead’s director of oncology, will deliver an oral presentation titled, “Development of an RNA Interference Therapeutic Targeting Angiopoietin-Like Protein 3 for Treatment of Hyperlipidemia”

First Results with RNA interference (RNAi) in Chronic Hepatitis B (CHB) Using ARO-HBV

• Publication Number: LB-25
• Session: Late-Breaking Poster Session
• Session Date and Time: November 12, 2018 from 8:00 AM to 5:30 PM PT
• Location: Moscone Center North/South Building, Hall C
• Authors: Dr. Edward J. Gane, et al.

A Phase 1 Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Effect of ARO-AAT on Serum Alpha-1 Antitrypsin levels in Normal Adult Volunteers

• Publication Number: LB-9
• Session: Late-Breaking Poster Session
• Session Date and Time: November 12, 2018 from 8:00 AM to 5:30 PM PT
• Location: Moscone Center North/South Building, Hall C
• Authors: Dr. Christian Schwabe, et al.

November 9, 11:15 a.m. PST – Dr. Given will deliver an oral presentation titled, “AROHBV1001 Results Update”

November 7, 3:35 p.m. EST – Bruce Given, M.D., Arrowhead’s chief operating officer, will deliver an oral presentation titled, “Clinical update on reducing HBV virus and antigen production using RNAi”

November 6, 11:20 a.m. CST – Zhen Li, Ph.D., Arrowhead’s senior vice president of chemistry and non-clinical development, will deliver a keynote presentation titled, “Discovery and Development of Arrowhead Clinical Candidates ARO-AAT and ARO-HBV”

Erik Bush, Ph.D., Arrowhead’s director of extra-hepatic targeting, will deliver a poster presentation titled, “A novel targeted RNAi molecule (TRiM™) delivery platform for the therapeutic inhibition of ENaC in cystic fibrosis lung disease”

Arrowhead management and external key opinion leaders will discuss Arrowhead’s emerging pipeline of RNAi therapeutics

Bruce Given, M.D., Arrowhead’s chief operating officer, will participate in a fireside chat.

October 5, 1:00 p.m. CEST –Christine Wooddell, Ph.D., Arrowhead’s director of liver targeting, will deliver a poster presentation titled, “Gene expression analysis during and after RNAi treatment of chronically HBV infected chimpanzees”